Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Cytokine and Visual Outcome Variations in Eyes Receiving Ranibizumab (COVERT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03056092
Recruitment Status : Recruiting
First Posted : February 17, 2017
Last Update Posted : September 19, 2019
Sponsor:
Information provided by (Responsible Party):
St. Michael's Hospital, Toronto

Brief Summary:

Objective: To determine the association between baseline aqueous cytokine levels and treatment intervals for patients under a variable dosing regimen with intravitreal ranibizumab in patients with neovascular age-related macular degeneration (nAMD), macular edema secondary to retinal vein occlusion (RVO) and diabetic macular edema (DME).

Methods: A prospective, single-centre study will be performed containing 3 sub-studies according to each study population: nAMD, macular edema secondary to RVO and DME. Inclusion criteria are: patients followed at St. Michael's Hospital with the diagnosis of nAMD, macular edema secondary to RVO or DME. Patients will be excluded if visual acuity is worse than counting fingers, with macular pathologies causing any structural changes to the retina, have received anti-VEGF injections or photocoagulation therapy 6 months prior to study, intraocular surgery 3 months prior to study, any history of vitreoretinal surgery or ocular inflammation in the study eye, use of systemic or topical anti-inflammatory or steroids, patients on dialysis for renal failure, allergy to the study drug or fluorescein, <18 years old, women who are pregnant. All patients will be treated with ranibizumab intravitreal injections on a variable dosing regimen: Patients with DME will be examined monthly and receive mandatory injection for the first three months (baseline, weeks 4 and 8). Afterwards, they will continue to be seen monthly and the need for new injections will be decided upon the clinical findings at each visit. An anterior chamber (AC) tap will be done if an injection is required at the visit. Patients with nAMD and RVO will be examined monthly and receive mandatory injection for the first three months. From weeks 12 until 72 (month 18), the visits will be scheduled at increasing 2-weeks intervals based on the stability of the ocular condition and response to treatment. At each visit, an injection and AC tap will be performed. The maximum interval in between injections is 12 weeks. If the disease becomes unstable, the interval in between injections is shortened and, once it stabilizes, the treatment frequency is extended again. In all patients, baseline aqueous humour specimens will be obtained prior to the first ranibizumab intravitreal injection and follow-up samples will be taken immediately prior to subsequent injections based on the treatment regimens for cytokine analysis in the end of the follow-up.


Condition or disease Intervention/treatment Phase
Age Related Macular Degeneration Diabetic Macular Edema Macular Edema Retinal Vein Occlusion Drug: Intravitreal ranibizumab Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 168 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: This study will include patients with 3 different diseases who will receive the same treatment (ranibizumab injections) but that will be independently analyzed. One population will be composed of patients with neovascular age related macular degeneration, the other of diabetic macular edema and the third of patients with macular edema secondary to retinal vein occlusion.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Cytokine and Visual Outcome Variations in Eyes Receiving a Variable Dosing Ranibizumab Treatment: The COVERT Study
Actual Study Start Date : February 28, 2017
Estimated Primary Completion Date : February 28, 2020
Estimated Study Completion Date : February 28, 2020

Resource links provided by the National Library of Medicine

Drug Information available for: Ranibizumab

Arm Intervention/treatment
AMD/RVO/DME
Patients presenting to St. Michael's Hospital retina clinic with neovascular age related macular degeneration, macular edema secondary to RVO and diabetic macular edema treated with intravitreal ranibizumab in a variable dosing regimen.
Drug: Intravitreal ranibizumab
Patients will be treated with intravitreal ranibizumab and have their aqueous humor obtained for cytokine analysis at every visit that an intravitreal injection is done




Primary Outcome Measures :
  1. Association between aqueous cytokine levels and optimal treatment interval [ Time Frame: 18 months ]
    Optimal treatment intervals based on aqueous cytokine levels


Secondary Outcome Measures :
  1. Individualized relationships between aqueous cytokines and treatment response [ Time Frame: 18 months ]
    Aqueous cytokine curves for each patient over based on the relationship between cytokine levels and treatment response

  2. Relationship between cytokine threshold level and visual/anatomic outcomes [ Time Frame: 18 months ]
    Cytokine threshold level below which visual and anatomic outcomes are greatest

  3. Snellen visual acuity change [ Time Frame: months 1, 2 and at every visit scheduled for each injection throughout 18 months period ]
    Snellen Best Corrected Visual Acuity (BCVA) change at months 1 and 2, and at the visits scheduled for each injection throughout an 18 months period

  4. ETDRS visual acuity change [ Time Frame: month 2, visits closest to injection of months 6, 12 and 18 ]
    Visual acuity (ETDRS) change at month 2 (at the third injection), at the visits closest to injection of months 6, 12 and 18.

  5. Optical coherence tomography (OCT) change [ Time Frame: months 1 and 2, and at the visits scheduled for each injection throughout an 18 months period. ]
    Anatomic OCT change (Macular Volume, Central Macular Thickness) at months 1 and 2, and at the visits scheduled for each injection throughout an 18 months period.

  6. Average number of injections needed [ Time Frame: 18 months ]
    Average number of injections needed in a variable dosing regimen protocol over an 18 months period.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of active choroidal neovascularization secondary to AMD in the study eye
  • Diagnosis of macular edema secondary to RVO: central macular thickness >310μm due to intraretinal or subretinal edema in the study eye as measured on OCT
  • Diagnosis of DME with central macular thickness >310μm in the study eye as measured on OCT in patients with diabetes mellitus types 1 or 2

Exclusion Criteria:

  • Previous intravitreal drug injections in either eye within 6 months prior to study enrollment
  • Visual acuity worse than counting fingers
  • Patients with other macular pathologies causing structural changes to the retina
  • Patients with large submacular hemorrhages or extensive fibrosis occupying the majority (>50%) of the lesion
  • Intraocular surgery in the study eye 3 months prior to study enrollment
  • Previous vitreoretinal surgery in the study eye
  • Previous photodynamic or macular photocoagulation therapy within the past 6 months in the study eye for patients with AMD
  • Previous photocoagulation therapy within 6 months in the study eye or anticipated need for during the course of the study for patients with RVO
  • Presence of active proliferative diabetic retinopathy or patients who have had pan-retinal photocoagulation within 6 months or patients where the need to pan-retinal photocoagulation is anticipated during the course of the study for patients with DME
  • History of intraocular inflammation in the study eye
  • Patients on systemic or topical anti-inflammatory or steroids medications
  • Patients receiving dialysis for renal failure
  • Known allergy to the study drug or fluorescein
  • Patients who are pregnant
  • Unwilling or unable to follow or comply with all study related procedures or to sign consent form

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03056092


Contacts
Layout table for location contacts
Contact: Rajeev Muni 416-867-7411 rajeev.muni@utoronto.ca

Locations
Layout table for location information
Canada, Ontario
Department of Ophthalmology, St Michael's Hospital Recruiting
Toronto, Ontario, Canada, M5C 2T2
Principal Investigator: Rajeev H Muni, FRCSC         
Canada
Sunnybrook Health Sciences Centre Recruiting
Toronto, Canada
Contact: Peter Kertes         
Sponsors and Collaborators
St. Michael's Hospital, Toronto
Investigators
Layout table for investigator information
Principal Investigator: Rajeev Muni St. Michael's Hospital, Toronto
Layout table for additonal information
Responsible Party: St. Michael's Hospital, Toronto
ClinicalTrials.gov Identifier: NCT03056092    
Other Study ID Numbers: COVERT
First Posted: February 17, 2017    Key Record Dates
Last Update Posted: September 19, 2019
Last Verified: September 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by St. Michael's Hospital, Toronto:
ranibizumab
aqueous cytokine
age related macular degeneration
diabetic macular edema
retinal vein occlusion
Additional relevant MeSH terms:
Layout table for MeSH terms
Macular Degeneration
Macular Edema
Retinal Vein Occlusion
Edema
Retinal Degeneration
Retinal Diseases
Eye Diseases
Venous Thrombosis
Thrombosis
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Ranibizumab
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents